Market Research Future (MRFR) recently Added a new report “Biologics Market”. The report further adds that the market will be reaching the valuation of USD 285,520.4 million by the end of 2023 and is on track to expand at a CAGR of 6.95% during the forecast period (2018-2023). Global Biologics Market Research Report: by Product (Monoclonal Antibody, Interleukins, Vaccines, Growth Factors, Gene Therapy, Others), by Disease Indication (Rheumatoid Arthritis, Psoriasis/Psoriatic Arthritis, Cancer, Diabetes, Others), by Manufacturing (In-house, Sourced), and Region – Forecast to 2023.
Biologics Market Drivers and Key Restraints
Data experts are predicting that the biologics market is on track to find greener pastures with increasing efforts and collective investments made towards the development of biologics with certain applications. An investment of more than USD 1.5 bn has been made by top 10 pharmaceutical companies in the past five years, translating into capacity expansion along with a rise in research and development. Numerous drug companies are earning massive profits due to premium prices that increase their profit margins between 20.0% and 40.0%. a predominant factor that is transforming the market dynamics is the growing product approvals on account of biologic’s ability to successfully treat highly complex diseases, which had been almost impossible in earlier times.
Get Free Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/1339
Additional drivers for the growth of the biologics market include surging incidence of chronic diseases and their diagnoses, easy availability of advanced diagnostics, increasing government initiatives in healthcare and progressing technological advancements in research and development by established drug makers. These drug companies are striving to maintain their position in the global market by giving stiff competition to their rivals, with one strategy being massive investments in incremental innovations.
On the downside, high capital investment needed for research and development could be a debilitating factor in the worldwide biologics market growth. But on the up side, MRFR report sheds light on the exciting news trends as well as opportunities making their way into the market that will help gain massive revenue in the forthcoming years. On that note, establishment of integrated facilities in markets with high potential, growing use of biologics as a preventive medicine and the presence of contract manufacturing organizations (CMOs) are expected to help the market sustain its growth in the years to come.
Global Biologic Market is Expected to Grow at a CAGR of 8.6% during Forecasted Period 2017-2023.
Introduction of Personalized Medicines Supports Market Growth
With drastic developments in gene and cell therapies, antibody drug conjugates and immunotherapies, the expected growth of biologics in the future is touted to be excellent. Trade pundits predict that biopharmaceuticals are poised to maintain their growth trend backed by innovative technologies and therapies. Personalized medicine and regenerative therapy are two areas that are developing at a speedy rate. Furthermore, personalized medicines that are based on immunotherapies, antibody drug conjugates and gene therapies are exhibited to be introduced in following years, which will offer lot of promise for regenerative medicine and focused disease remission. Key Players for Global Biologics Market
- Sanofi (France),
- Pfizer Inc. (U.S.),
- Amgen (U.S.),
- Hoffman-La Roche AG (Switzerland),
- AbbVie Inc. (U.S.),
- Bayer AG (Germany),
- AstraZeneca (U.K.),
- GlaxoSmithKline Plc (U.K.),
- Novartis AG (Switzerland),
- Eli Lilly and Company (U.S.),
are among some of the leading companies in the global biologics market.
Five players out of these are at the top with over 70% share of the total market, which are Roche, AbbVie, Amgen, GSK and Pfizer.
April 2019 – WuXi Biologics and NBE-Therapeutics (NBE) have entered into a partnership and are in the process of developing and manufacturing NBE’s first ADC lead product known as NBE-002 (anti-ROR1). The product refers to an immune-stimulatory ADC (iADC) treatment that protects against ROR1 cancer target.
February 19, 2019 – WuXi Biologics (China), a leading pharmaceutical preparation manufacturing company announced the completion European Medicines Agency (EMA) the pre-approval inspection (PAI) of the company’s cGMP drug substance (DS) and drug product (DP) manufacturing facilities for the production of TaiMed Biologics’ Trogarzo with no critical findings. This inspection result manifests WuXi’s world-class quality system that meets global quality standards.
Also, this is a critical milestone For WuXi Bio, as the EMA inspection is the first of its kind in China. The responses will be submitted to the EMA inspection report in March this year by the Chinese CDMO and the GMP certification for its facilities is expected by May 2019.
Browse Complete Report @ https://www.marketresearchfuture.com/reports/biologics-market-1339
February 20, 2019 – The Infectious Disease Research Institute (IDRI – the US), a non-profit organization announced its partnership with Biovac Institute (South Africa), a vaccine manufacturer and Afrigen Biologics and Vaccines (South Africa), a start-up venture involved in the development and production of vaccines, biologics and adjuvants to produce tuberculosis vaccine, transferring technology to SA for on-site vaccine production.
Global Biologics Industry Competitive Analysis
The geographical distribution of the global biologics market has been considered for the regions of the Americas, the Middle East & Africa (MEA), Europe and Asia Pacific (APAC).
Geography-wise, the regions of North America and Europe are currently reigning over the global biologics market, trailed by Asia Pacific. The increasing technological advancement in healthcare accompanied by systematic drug review processes are bound to create more growth opportunities for the market in North America. Other supplementary factors helping with the growth of the North America biologics market include expanding capital investment from critical vendors, growing prevalence of chronic diseases, rising demand and higher acceptability of advanced therapies among others. High population and continuous changes in social behavior are other indirect reasons backing the growth of the regional market in the long run.
The other lucrative region currently dominating the global biologics market is Europe, which is driven by highly advanced healthcare infrastructure coupled with elevated awareness and regulatory harmonization among patients. Adding on, surging funding for the development of biologics that are available via public-private partnerships, availability of well-established research infrastructure as well as novel strategies being adopted by drug makers to restrict new players from entering the market are other strong factors backing the growth of the regional market.
With the increasing middle-class population and the rapid urbanization, more people in the Middle East and Africa are adopting an inactive lifestyle. This factor will play a major role in the growth of the market in the region.
Segments for Global Biologics Market
The market for biologics is segmented on the basis of product, disease indication, and manufacturing.
The product-wise segments in the biologics market include monoclonal antibody, interleukins, vaccines, growth factors, gene therapy, and others. Monoclonal antibody market is poised to reach the size of USD 92,597.4 million at a CAGR of 3.44% during the assessment period. The growth of the market has been the result of the growing use of monoclonal antibodies (mAbs) for enhancing the immunity system. On the other hand, vaccines made for about 21% of the total market in the year 2017, and is growing at the fastest rate in the forthcoming years. It is on its way to exhibit 6.75% CAGR, and is predicted to reach the valuation of USD 66,743.5 million by the end of the review period.
Based on disease indication, the market has been considered for cancer, diabetes, rheumatoid arthritis, psoriasis/psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, Crohn’s disease, juvenile idiopathic arthropathy, cardiovascular diseases, and others. Among these, in 2018, cancer controlled close to 19.2% share of the biologics market, whereas the rheumatoid arthritis segment is expected to topple the cancer segment from the top position by 2023. The segment will be representing a CAGR of 8.78% in the coming years, on account of the rapid approval of diverse types of drugs by the regulatory agencies.
Manufacturing-wise, two major methods covered in the report are outsourced and in-house. Out of these, the latter will exhibit a higher growth rate as a result of the presence of pharmaceutical companies, especially emerging companies that are researching the formulations at a very cheap price. Also, the outsourced segment is deemed to garner revenue of almost USD 112,162.4 million by 2023.
Regional Analysis for Global Biologics Market
The North American region, heading with its well-developed healthcare sector accounts for the leading position in the global biologics market followed by the European and Asia Pacific region, respectively. Simultaneously, factors such as the high-volume production of pharmaceuticals and the huge demand for biologics led by the high healthcare expenditure.
Undoubtedly, the availability and the wide uptake of new technologies to develop advanced production methods is positively impacting market growth. The US, backed by the huge technological advancements in the field of manufacturing biologics leads the regional market.
The European region owns the next largest share in the global biologics market, following the North American market closely. Factors propelling the growth of the regional market include the resurging economy that is availing the best possible healthcare & substantially high healthcare expenditures and the government support that encourages manufacturers of biologics to develop new and effective biologics.
Get Exclusive Discount on Report @ https://www.marketresearchfuture.com/check-discount/1339
The Asia Pacific region is emerging as a profitable market for biologics due to the rapidly improving healthcare infrastructure. Moreover, factors such as the ever-increasing population that is continually dictating the demand for quality healthcare and the spreading awareness towards the availability and benefits of biologics are positively impacting the growth in the regional market.
Rapidly developing economies are expected to provide immense opportunities for the growth of biologics. Also, the increasing adoption of technologies is positively impacting market growth in the region. Furthermore, rising healthcare concerns along with the fast-proliferating healthcare sector, increase the market size of the biologics market in the APAC.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar